NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05089734 2025-05-23
EVOKE-01
Gilead Sciences
Phase 3 Active not recruiting
NCT03725761 2025-05-13
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting